Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States.
Undervalued with adequate balance sheet.
Share Price & News
How has Supernus Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SUPN has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: SUPN underperformed the US Pharmaceuticals industry which returned 12.6% over the past year.
Return vs Market: SUPN underperformed the US Market which returned 24.7% over the past year.
Price Volatility Vs. Market
How volatile is Supernus Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StDid Business Growth Power Supernus Pharmaceuticals's (NASDAQ:SUPN) Share Price Gain of 160%?
1 month ago | Simply Wall StSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN): What Does Its Beta Value Mean For Your Portfolio?
1 month ago | Simply Wall StDo You Know What Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) P/E Ratio Means?
Is Supernus Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SUPN ($23.79) is trading below our estimate of fair value ($60.73)
Significantly Below Fair Value: SUPN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SUPN is good value based on its PE Ratio (11.8x) compared to the Pharmaceuticals industry average (24.9x).
PE vs Market: SUPN is good value based on its PE Ratio (11.8x) compared to the US market (18.9x).
Price to Earnings Growth Ratio
PEG Ratio: SUPN's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: SUPN is good value based on its PB Ratio (2.2x) compared to the US Pharmaceuticals industry average (3.3x).
How is Supernus Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SUPN's earnings are forecast to decline over the next 3 years (-9.5% per year).
Earnings vs Market: SUPN's earnings are forecast to decline over the next 3 years (-9.5% per year).
High Growth Earnings: SUPN's earnings are forecast to decline over the next 3 years.
Revenue vs Market: SUPN's revenue is expected to decline over the next 3 years (-0.3% per year).
High Growth Revenue: SUPN's revenue is forecast to decline over the next 3 years (-0.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SUPN's Return on Equity is forecast to be high in 3 years time
How has Supernus Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SUPN has high quality earnings.
Growing Profit Margin: SUPN's current net profit margins (25.9%) are higher than last year (25.9%).
Past Earnings Growth Analysis
Earnings Trend: SUPN has become profitable over the past 5 years, growing earnings by 43.3% per year.
Accelerating Growth: SUPN's earnings growth over the past year (7.2%) is below its 5-year average (43.3% per year).
Earnings vs Industry: SUPN earnings growth over the past year (7.2%) underperformed the Pharmaceuticals industry 36.8%.
Return on Equity
High ROE: SUPN's Return on Equity (19%) is considered low.
Return on Assets
Return on Capital Employed
How is Supernus Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: SUPN's short term assets ($427.1M) exceed its short term liabilities ($149.7M).
Long Term Liabilities: SUPN's short term assets ($427.1M) exceed its long term liabilities ($399.9M).
Debt to Equity History and Analysis
Debt Level: SUPN's debt to equity ratio (61.2%) is considered high.
Reducing Debt: SUPN's debt to equity ratio has increased from 40.2% to 61.2% over the past 5 years.
Debt Coverage: SUPN's debt is well covered by operating cash flow (38.7%).
Interest Coverage: SUPN's interest payments on its debt are well covered by EBIT (65.1x coverage).
Inventory Level: SUPN has a low level of unsold assets or inventory.
Debt Coverage by Assets: SUPN's debt is covered by short term assets (assets are 1.3x debt).
What is Supernus Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate SUPN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate SUPN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SUPN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SUPN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SUPN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
What is the CEO of Supernus Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
Average management tenure
Jack Khattar (58yo)
Mr. Jack A. Khattar founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has been its Chief Executive Officer, President, Secretary and Director since 2005. From 1999 to ...
CEO Compensation Analysis
Compensation vs Market: Jack's total compensation ($USD7.22M) is above average for companies of similar size in the US market ($USD3.86M).
Compensation vs Earnings: Jack's compensation has increased by more than 20% in the past year.
Management Age and Tenure
Experienced Management: SUPN's management team is seasoned and experienced (7.5 years average tenure).
Board Age and Tenure
Experienced Board: SUPN's board of directors are considered experienced (6.9 years average tenure).
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Chief Executive Officer
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Jack Khattar (58yo)
- Tenure: 15yrs
- Compensation: US$7.22m
Gregory Patrick (68yo)
Senior VP & CFO
- Tenure: 8.2yrs
- Compensation: US$1.24m
Padmanabh Bhatt (62yo)
Chief Scientific Officer & Senior VP of Intellectual Property
- Tenure: 7.8yrs
- Compensation: US$1.23m
Tami Martin (64yo)
Senior Vice President of Regulatory Affairs
Stefan K. Schwabe (67yo)
Chief Medical Officer and Executive VP of Research & Development
- Tenure: 7.5yrs
- Compensation: US$1.28m
Vice President of Marketing
- Tenure: 5yrs
Vice President of Sales
- Tenure: 5yrs
Vice President of Corporate Development
- Tenure: 4.5yrs
Chuck Newhall (74yo)
Chairman of the Board
- Tenure: 3.4yrs
- Compensation: US$298.13k
John Siebert (79yo)
- Tenure: 9yrs
- Compensation: US$277.13k
Jack Khattar (58yo)
- Tenure: 15yrs
- Compensation: US$7.22m
Georges Gemayel (59yo)
- Tenure: 4.8yrs
- Compensation: US$267.13k
Carrolee Barlow (55yo)
- Tenure: 1.6yrs
- Compensation: US$365.09k
Frederick Hudson (74yo)
- Tenure: 10yrs
- Compensation: US$282.13k
Supernus Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Supernus Pharmaceuticals, Inc.
- Ticker: SUPN
- Exchange: NasdaqGM
- Founded: 2005
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.283b
- Shares outstanding: 52.46m
- Website: https://www.supernus.com
Number of Employees
- Supernus Pharmaceuticals, Inc.
- 1550 East Gude Drive
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SUPN||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||May 2012|
|S49||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 2012|
|0LB2||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||May 2012|
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The company’s product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy. The company markets its products through wholesalers and distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/01/18 00:20|
|End of Day Share Price||2020/01/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.